WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H319615
CAS#: 82586-52-5 (HCl salt); 103775-10-6 (free base).
Description: Moexipril is a potent orally active nonsulfhydryl angiotensin converting enzyme inhibitor (ACE inhibitor) which is used for the treatment of hypertension and congestive heart failure. Moexipril can be administered alone or with other antihypertensives or diuretics. It works by inhibiting the conversion of angiotensin I to angiotensin II.
Hodoodo Cat#: H319615
Name: Moexipril hydrochloride
CAS#: 82586-52-5 (HCl salt); 103775-10-6 (free base).
Chemical Formula: C27H35ClN2O7
Exact Mass: 0.00
Molecular Weight: 535.034
Elemental Analysis: C, 60.61; H, 6.59; Cl, 6.63; N, 5.24; O, 20.93
Synonym: RS 10085; RS-10085; RS10085; SPM-925; SPM 925; SPM925; CI-925; CI 925; CI925; Moexipril. trade name Univasc.
IUPAC/Chemical Name: 2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride
InChi Key: JXRAXHBVZQZSIC-QGCARJLFSA-N
InChi Code: InChI=1S/C27H34N2O7.ClH/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32;/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32);1H/t17-,21-,22?;/m0./s1
SMILES Code: O=C(C1N(C([C@@H](N[C@H](C(OCC)=O)CCC2=CC=CC=C2)C)=O)CC3=C(C=C(OC)C(OC)=C3)C1)O.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 535.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Chrysant GS, Nguyen PK. Moexipril and left ventricular hypertrophy. Vasc Health Risk Manag. 2007;3(1):23-30. Review. PubMed PMID: 17583172; PubMed Central PMCID: PMC1994034.
2: Ostroumova OD, Paukov SV, Frolova LI. [Angiotensin converting enzyme inhibitor moexipril in the treatment of arterial hypertension. Possibilities of moexipril in the treatment of postmenopausal women]. Kardiologiia. 2006;46(11):92-8. Review. Russian. PubMed PMID: 17159885.
3: [Moexipril and cardiovascular diseases in women: is there a reason for optimism?]. Kardiologiia. 2006;46(7):81-4. Review. Russian. PubMed PMID: 16883271.
4: Chrysant SG, Chrysant GS. Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. Review. PubMed PMID: 15286086.
5: Chrysant SG, Chrysant GS. Pharmacological profile and clinical use of moexipril. Expert Rev Cardiovasc Ther. 2003 Sep;1(3):345-52. Review. PubMed PMID: 15030263.
6: Pines A, Fisman EZ. ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control. Am J Cardiovasc Drugs. 2003;3(5):351-60. Review. PubMed PMID: 14728069.
7: Brogden RN, Wiseman LR. Moexipril. A review of its use in the management of essential hypertension. Drugs. 1998 Jun;55(6):845-60. Review. PubMed PMID: 9617599.
